Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 2Tumor With Alterations of the FGF-R 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioblastoma 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Gastrointestinal Stromal Tumor (GIST) 1Acrocephalosyndactylia 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × infigratinib × Clear all
NCT04233567 2026-02-24

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
17 enrolled 12 charts
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡